Table of Contents Author Guidelines Submit a Manuscript
The Scientific World Journal
Volume 2014, Article ID 368947, 6 pages
http://dx.doi.org/10.1155/2014/368947
Clinical Study

Dynamic Metabolic Changes during the First 3 Months after 90Y-Ibritumomab Tiuxetan Radioimmunotherapy

1Department of Radiology, Graduate School of Medicine, The University of Tokyo, 3-1 Hongo 7-Chome, Bunkyo-ku, Tokyo 113-8655, Japan
2Department of Hematology and Oncology, Graduate School of Medicine, The University of Tokyo, 3-1 Hongo 7-Chome, Bunkyo-ku, Tokyo 113-8655, Japan

Received 31 January 2014; Accepted 3 June 2014; Published 19 June 2014

Academic Editor: Akihiro Takano

Copyright © 2014 Miwako Takahashi et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. B. D. Cheson, S. J. Horning, B. Coiffier et al., “Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas,” Journal of Clinical Oncology, vol. 17, no. 4, pp. 1244–1253, 1999. View at Google Scholar · View at Scopus
  2. M. E. Juweid, S. Stroobants, O. S. Hoekstra et al., “Use of positron emission tomography for response assessment of lymphoma: consensus of the imaging subcommittee of international harmonization project in lymphoma,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 571–578, 2007. View at Publisher · View at Google Scholar · View at Scopus
  3. B. D. Cheson, B. Pfistner, M. E. Juweid et al., “Revised response criteria for malignant lymphoma,” Journal of Clinical Oncology, vol. 25, no. 5, pp. 579–586, 2007. View at Publisher · View at Google Scholar
  4. L. Kostakoglu, S. J. Goldsmith, J. P. Leonard et al., “FDG-PET after 1 cycle of therapy predicts outcome in diffuse large cell lymphoma and classic Hodgkin disease,” Cancer, vol. 107, no. 11, pp. 2678–2687, 2006. View at Publisher · View at Google Scholar · View at Scopus
  5. V. Safar, J. Dupuis, E. Itti et al., “Interim [18F]fluorodeoxyglucose positron emission tomography scan in diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy plus rituximab,” Journal of Clinical Oncology, vol. 30, no. 2, pp. 184–190, 2012. View at Publisher · View at Google Scholar · View at Scopus
  6. P. L. Zinzani, L. Rigacci, V. Stefoni et al., “Early interim 18F-FDG PET in Hodgkin's lymphoma: evaluation on 304 patients,” European Journal of Nuclear Medicine and Molecular Imaging, vol. 39, no. 1, pp. 4–12, 2012. View at Publisher · View at Google Scholar · View at Scopus
  7. A. Orlacchio, O. Schillaci, E. Gaspari et al., “Role of [18F]-FDG-PET/MDCT in evaluating early response in patients with Hodgkin's lymphoma,” Radiologia Medica, vol. 117, no. 7, pp. 1250–1263, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. A. Gallamini, M. Hutchings, L. Rigacci et al., “Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: a report from a joint Italian-Danish study,” Journal of Clinical Oncology, vol. 25, no. 24, pp. 3746–3752, 2007. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Hutchings, A. Loft, M. Hansen et al., “FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma,” Blood, vol. 107, no. 1, pp. 52–59, 2006. View at Publisher · View at Google Scholar · View at Scopus
  10. P. Polakis, “Arming antibodies for cancer therapy,” Current Opinion in Pharmacology, vol. 5, no. 4, pp. 382–387, 2005. View at Publisher · View at Google Scholar
  11. T. E. Witzig, L. I. Gordon, F. Cabanillas et al., “Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma,” Journal of Clinical Oncology, vol. 20, no. 10, pp. 2453–2463, 2002. View at Publisher · View at Google Scholar · View at Scopus
  12. T. E. Witzig, A. Molina, L. I. Gordon et al., “Long-term responses in patients with recurring or refractory B-cell non-Hodgkin lymphoma treated with yttrium 90 ibritumomab tiuxetan,” Cancer, vol. 109, no. 9, pp. 1804–1810, 2007. View at Publisher · View at Google Scholar · View at Scopus
  13. K. Tobinai, T. Watanabe, M. Ogura et al., “Japanese phase II study of 90Y-ibritumomab tiuxetan in patients with relapsed or refractory indolent B-cell lymphoma,” Cancer Science, vol. 100, no. 1, pp. 158–164, 2009. View at Publisher · View at Google Scholar · View at Scopus
  14. G. Storto, A. de Renzo, T. Pellegrino et al., “Assessment of metabolic response to radioimmunotherapy with 90Y-ibritumomab tiuxetan in patients with relapsed or refractory B-cell non-Hodgkin lymphoma,” Radiology, vol. 254, no. 1, pp. 245–252, 2010. View at Publisher · View at Google Scholar · View at Scopus
  15. W. Romer, A. Hanauske, S. Ziegler et al., “Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose,” Blood, vol. 91, no. 12, pp. 4464–4471, 1998. View at Google Scholar · View at Scopus
  16. I. Trigonis and A. Jackson, “Imaging pharmacodynamics in oncology: the potential significance of ‘flares’,” Annals of Nuclear Medicine, vol. 24, no. 3, pp. 137–147, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. R. M. Macklis, B. A. Beresford, and J. L. Humm, “Radiobiologic studies of low-dose-rate 90Y-lymphoma therapy,” Cancer, vol. 73, supplement 3, pp. 966–973, 1994. View at Google Scholar · View at Scopus
  18. G. A. Wiseman, C. A. White, T. E. Witzig et al., “Radioimmunotherapy of relapsed non-Hodgkin's lymphoma with Zevalin, a 90Y-labeled anti-CD20 monoclonal antibody,” Clinical Cancer Research, vol. 5, supplement 10, pp. 3281s–3286s, 1999. View at Google Scholar · View at Scopus
  19. T. Torizuka, K. R. Zasadny, P. V. Kison, S. G. Rommelfanger, M. S. Kaminski, and R. L. Wahl, “Metabolic response of non-Hodgkin's lymphoma to 131I-anti-B1 radioimmunotherapy: evaluation with FDG PET,” Journal of Nuclear Medicine, vol. 41, no. 6, pp. 999–1005, 2000. View at Google Scholar · View at Scopus